Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 153 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lopinavir/ritonavir Clear all
Terminated Not applicable Interventional Results available

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study

NCT00344487
View directory record Official record
Conditions
HIV
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

NCT01003990
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine, Lopinavir/ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 3, 2026, 2:02 AM EDT
Terminated Phase 4 Interventional

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

NCT00981318
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
lopinavir/ritonavir plus maraviroc
Drug
Lead sponsor
Rodwick, Barry M., M.D.
Individual
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Safety Harbor, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 3, 2026, 2:02 AM EDT
Terminated Phase 4 Interventional

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

NCT00100984
View directory record Official record
Conditions
HIV Infection
Interventions
FUZEON [enfuvirtide]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
20
States / cities
Hobson City, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

NCT00955968
View directory record Official record
Conditions
HIV Infection
Interventions
Highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Alhambra, California • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 3, 2026, 2:02 AM EDT
Completed No phase listed Observational

Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen

NCT00200369
View directory record Official record
Conditions
HIV Infection
Interventions
MEMS cap
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
19 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2009 · Synced Oct 3, 2026, 2:02 AM EDT
Not listed Not applicable Interventional

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

NCT00247143
View directory record Official record
Conditions
HIV, AIDS
Interventions
Kaletra (drug)
Drug
Lead sponsor
Lampiris, Harry W., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2006 · Synced Oct 3, 2026, 2:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

HIV Antiretroviral Drugs and Metabolism

NCT00525239
View directory record Official record
Conditions
HIV Infections
Interventions
ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

LAAM-HAART PET Imaging

NCT01935830
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11c] LAAM, Ritonavir, Efavirenz
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 3, 2026, 2:02 AM EDT
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 3, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

NCT00259727
View directory record Official record
Conditions
Diabetes, HIV Infections, Insulin Resistance
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 72 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19

NCT04372628
View directory record Official record
Conditions
COVID-19
Interventions
Lopinavir/Ritonavir 400 mg/100 mg, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV

NCT00084149
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, and Zidovudine, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)

NCT01227590
View directory record Official record
Conditions
Drug Interactions, Human Immunodeficiency Virus
Interventions
Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 3, 2026, 2:02 AM EDT
Completed No phase listed Observational

Sex, Aging and Antiretroviral Pharmacokinetics

NCT00666055
View directory record Official record
Conditions
HIV Infections
Interventions
ARV regimen chosen by treating physician
Drug
Lead sponsor
Kristine Patterson, MD
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 3, 2026, 2:02 AM EDT
Not listed Phase 3 Interventional

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

NCT00025727
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Ritonavir, GW433908
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
32
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Not applicable Interventional

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

NCT00028366
View directory record Official record
Conditions
HIV Infections
Interventions
Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Phase 3 Interventional

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Not applicable Interventional Results available

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

NCT00884793
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, Study NNRTI, Study PI
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 3, 2026, 2:02 AM EDT
Terminated Phase 4 Interventional Results available

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Lopinavir/Ritonavir, Truvada
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 3, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

NCT01148004
View directory record Official record
Conditions
HIV, Fenofibrate, Protease Inhibitors, Hypertriglyceridemia, Glucuronosyltransferase
Interventions
Fenofibrate, Ritonavir, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 3, 2026, 2:02 AM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 3, 2026, 2:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 48 Hours
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 3, 2026, 2:02 AM EDT